Anti-Human IL-17 (Bimekizumab) – Fc Muted™

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bimekizumab. UCB4940 (Bimekizumab) is a dual inhibitor of IL-17A and IL-17F interleukins.

Interleukin 17 (IL-17) is a pro-inflammatory cytokine crucial to host defense, tissue repair, pathogenesis of inflammatory disease, and progression of cancer¹. IL-17 signaling is also critical for protection against fungal and bacterial infection². There are six pro-inflammatory cytokines (IL-17A-F) produced by Th17 cells³. IL-17A and IL-17F share ~50% structural homology⁴ as well as overlapping biological functions in chronic inflammation and adaptive immune defense from bacterial and fungal infection⁵. Additionally, they are coexpressed in immune- inflammatory diseases⁵. IL-17A and IL-17F drive pathogenesis in psoriasis⁵ and are both found in lesional skin and inflamed synovium from patients with psoriatic arthritis⁴. Since dual neutralization of IL-17A and IL-17F results in lower expression of inflammation-linked genes and cytokines 4 and because targeting the IL-17 pathway has clinical efficacy⁵, an antibody therapeutic designed to potently and selectively neutralize both IL-17A and IL-17F is desirable.

Bimekizumab is a humanized monoclonoal antibody designed to bind at a similar site on both IL-17A and IL-17F, allowing for dual inhibition⁵. Bimekizumab has been approved for use in the treatment of plaque psoriasis⁶, psoriatic arthritis⁷, and axial spondyloarthritis⁸.

Th17 cells, which are CD4 + T-helper cells, are the principal source of IL- 17. Tc17 cells, which are CD8 + cells, also make IL-17. Additionally, IL-17 is produced by a number of innate immune subsets (γδ-T cells, some natural killer T (NKT) cells, TCRβ+ ‘natural’ Th17 cells, and Type 3 “innate lymphoid cells” (ILC3)) and possibly by myeloid cells in small amounts.

IL17RA-IL17RC heterodimeric receptor complex

IL-17A: Q16552
IL-17F: Q96PD4

1 Li X, Bechara R, Zhao J, et al. Nat Immunol. 20(12):1594-1602. 2019.
2 Amatya N, Garg AV, Gaffen SL. Trends Immunol. 38(5):310-322. 2017.
3 Golbari NM, Basehore BM, Zito PM. Brodalumab. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470324/
4 Papp KA, Merola JF, Gottlieb AB, et al. J Am Acad Dermatol. 79(2):277-286.e10. 2018.
5 Glatt S, Helmer E, Haier B, et al. Br J Clin Pharmacol. 83(5):991-1001. 2017.
6 Kaplon H, Chenoweth A, Crescioli S, et al. MAbs. 14(1):2014296. 2022.
7 Nie T, Shirley M. Drugs. 84(5):587-598. 2024.
8 Baraliakos X, Deodhar A, van der Heijde D, et al. Ann Rheum Dis. 83(2):199-213. 2024.